Investor Relations > details

Zensun Obtained Initial Results of Australian Clinical Study


In 2006, Zensun initiated Phase IIa clinical study of its heart failure drug—rhNRG-1. After one and half years’ research, Zensun obtained exciting results.

The research involved three different dosages groups. It showed that the systolic function of patients with medium and high dosages improved significantly, comparing to the patients with the low dosage. This result is also consistent with the results achieved from Chinese Phase II clinical trial. 

Now, Zensun are going to put more investment to facilitate the process of clinical trials.